HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Owner Of Florida Firm Sent To Prison After Contaminated OTCs Linked To Infant Deaths

Executive Summary

Firm’s problems “illustrate just how important it is for senior managers to prioritize manufacturing quality, to prioritize patient safety and prevent the absolutely tragic consequences that resulted here,” says Don Ashley, CDER compliance office director.

You may also be interested in...



Florida Firm’s Failure To List All Potentially Contaminated Products Leads To Criminal Charges

FDA Office of Criminal Investigations says Raidel Figueroa, former co-owner of Pharmatech in Broward County, is charged with as conspiracy “to manufacture and distribute drugs outside the regulatory oversight of the FDA, to interfere with and obstruct the FDA” in its investigation of Pharmatech’s manufacturing of an OTC monograph constipation treatment.

PharmaTech Recalls Highlight Supplement GMP Diligence For Marketers – CRN

PharmaTech customers recall liquid supplements, including products indicated for children, after CDC informs FDA that an antibiotic-resistant pathogen was found in a PharmaTech Rx drug. CRN says the recall should remind supplement firms about tracking supply chains and auditing contract manufacturers.

US FDA Portal Open To Receive OTC Monograph Meeting Requests

Submitting other OTC monograph program communications through CDER's NextGen Portal, including proposals to add formulations or indications to a monograph, will have to wait.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152933

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel